Skip to content
NASDAQ · PHARMACEUTICAL PREPARATIONS

Elicio Therapeutics, Inc. ELTX

6 fiscal years on record · USD · FY2025 reported · SEC filings only
$-39.6M
$-37.0M

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

In brief

What this company does

As of December 31, 2025, we had 33 employees, all of whom were full-time, 9 of whom have Ph.D. or M.D. degrees, and 25 of whom are engaged in research and development and manufacturing activities. Elicio Therapeutics, Inc. (“Elicio” or the “Company”) was incorporated in Delaware as Vedantra Pharmaceuticals Inc. in August 2011. and Angion changed its name from “Angion Biomedica Corp.” to “Elicio Therapeutics, Inc.”

Written from the business description in Elicio Therapeutics, Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 12 March 2026. Every sentence was checked against that document before publication.

Growth

·
Revenue, FY2025 · full 6-year series below
Revenue $M Net income $M
FY2022 · Revenue 2.3 · Net income -28.2
10M20M-30M-60M
202020232025
Compound annual growth
3 yrs
5 yrs
10 yrs
15 yrs

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

·
Operating margin Net margin
FY2022 · Operating -1031.4% · Net -1225.9%
-500%-1000%-1500%
202020222025
ROE

Not applicable: equity was zero or negative in this period, so return on equity has no meaning.

Three returns, three denominators.
Return on equityNot applicable: equity was zero or negative in this period, so return on equity has no meaning.

Return on equity has no reading this year — return on capital employed, just below, still does: -219%.

Cash & shareholders

·
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -37.0
-20M-40M
202020222025

Total assetsUSD 25.9M
EquityUSD 1.6M
CashUSD 18.6M
Gross debtUSD 9.4M
Net debtUSD -9.2M
Current ratio2.38×

The company holds more cash than debt.

The 6-year record

6 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
ELTX, 6-year financial record
Metric 202520242023202220212020
Revenue $B◌◌◌0.00.00.0
Operating income $B−0.0−0.0−0.0−0.0−0.0−0.1
EBITDA $B−0.0−0.0−0.0−0.0−0.0−0.1
Income tax $B0.00.00.00.00.00.0
Net income $B−0.0−0.1−0.0−0.0−0.1−0.1
Free cash flow $B−0.0−0.0−0.0−0.0−0.1−0.0
EPS, diluted $−2.58−4.25−6.96−89.27−1.93−5.43
Dividend / sh $◌◌◌◌◌◌
Payout % — not applicable: no dividend——————
ROE % — not applicable: negative equity——————
Shares out B0.020.010.010.000.030.02

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 0 failures in 24 reconciliationsAUDITED

Reconciled in 6 of the 6 fiscal years we could check. 26 checks were skipped: the balance sheet is not tagged before 2020. 13 checks were skipped: EPS is not tagged before 2020. 13 checks were skipped: revenue is not tagged before 2020.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categoryemerging growth company
Data on record since2020

Share this section

Download image